Dr. Daniel K. Bennett, MD
Retina Specialist (Retina Specialist (Ophthalmology) Physician)
- Medicare participating
At a glance
- Medical school
- University of Virginia School of Medicine (2008)
- Years since graduation
- 18
- In the NPI registry since
- 2008
- Medicare patients seen, 2024
- 1,224
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2008Medical school: University of Virginia School of Medicine
- 2008Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Retina Specialist (Ophthalmology) Physician primary
NC license 2014-00307 -
Ophthalmology Physician
AL license MD.31640 · NC license 2014-00307 - Student in an Organized Health Care Education/Training Program
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Rex Hospital Raleigh, NC
Medical groups
- Retina Associates, PLLC (17 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 1,224
- Services billed
- 29,456
- Patients’ average age
- 77
| Service | Times | Patients |
|---|---|---|
| Injection, faricimab-svoa, 0.1 mg | 5,760 | 21 |
| Injection, aflibercept, 1 mg | 2,178 | 199 |
| Injection, ranibizumab, 0.1 mg | 2,138 | 77 |
| Injection of drug into eye | 1,756 | 360 |
| Photography of the retina | 1,728 | 1,127 |
| Established patient office or other outpatient visit, 20-29 minutes | 1,474 | 945 |
| Imaging of retina | 1,416 | 420 |
| Injection, ranibizumab-nuna, biosimilar, (byooviz), 0.1 mg | 1,400 | 43 |
| Injection, ranibizumab-eqrn (cimerli), biosimilar, 0.1 mg | 521 | 38 |
| New patient office or other outpatient visit, 45-59 minutes | 197 | 197 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Prednisolone Acetate Other prescribers in Raleigh, NC | 184 |
| Tobramycin | 81 |
| Latanoprost Other prescribers in Raleigh, NC | 64 |
| Dorzolamide-Timolol (dorzolamide hcl/timolol maleat) Other prescribers in Raleigh, NC | 59 |
| Timolol Maleate Other prescribers in Raleigh, NC | 25 |
| Brimonidine Tartrate Other prescribers in Raleigh, NC | 18 |
| Fluorometholone Other prescribers in Raleigh, NC | 11 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 7 companies reported 41 payments worth $3,346 in total to this clinician.
| Astellas Pharma US Inc | $2,117 |
|---|---|
| Regeneron Healthcare Solutions, Inc. | $537 |
| Harrow Eye, LLC | $225 |
| Alcon Vision LLC | $225 |
| Apellis Pharmaceuticals, Inc. | $149 |
| AbbVie Inc. | $49.10 |
| Genentech USA, Inc. | $43.90 |
| Consulting Fee | $2,000 |
|---|---|
| Food and Beverage | $1,346 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Astellas Pharma US Inc Mar 7, 2025 | Consulting Fee Izervay · Ophthalmology | $2,000 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.